Halozyme and Incyte Collaborate on Enhanze Technology for Myeloproliferative Neoplasm Candidate
Halozyme has entered a global collaboration with Incyte to use its Enhanze drug delivery technology in the development of INCA033989, an experimental monoclonal antibody targeting myeloproliferative neoplasms. The partnership aims to enhance the therapeutic potential and delivery efficiency for this first-in-class candidate.
